BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Brent MB. Abaloparatide: A review of preclinical and clinical studies. Eur J Pharmacol 2021;909:174409. [PMID: 34364879 DOI: 10.1016/j.ejphar.2021.174409] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Huang H, Ma S, Xing X, Su X, Xu X, Tang Q, Gao X, Yang J, Li M, Liang C, Wu Y, Liao L, Tian W. Muscle-derived extracellular vesicles improve disuse-induced osteoporosis by rebalancing bone formation and bone resorption. Acta Biomater 2023;157:609-24. [PMID: 36526242 DOI: 10.1016/j.actbio.2022.12.019] [Reference Citation Analysis]
2 Brent MB, Emmanuel T. Contemporary Advances in Computer-Assisted Bone Histomorphometry and Identification of Bone Cells in Culture. Calcif Tissue Int 2023;112:1-12. [PMID: 36309622 DOI: 10.1007/s00223-022-01035-2] [Reference Citation Analysis]
3 Dimai HP, Fahrleitner-Pammer A. Osteoporosis and Fragility Fractures: currently available pharmacological options and future directions. Best Pract Res Clin Rheumatol 2022;36:101780. [PMID: 36163230 DOI: 10.1016/j.berh.2022.101780] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Lin P, Zhang W, Chen D, Yang Y, Sun T, Chen H, Zhang J. Electrospun nanofibers containing chitosan-stabilized bovine serum albumin nanoparticles for bone regeneration. Colloids Surf B Biointerfaces 2022;217:112680. [PMID: 35803032 DOI: 10.1016/j.colsurfb.2022.112680] [Reference Citation Analysis]
5 Mcclung MR, Rothman MS, Lewiecki EM, Hanley DA, Harris ST, Miller PD, Kendler DL. The role of osteoanabolic agents in the management of patients with osteoporosis. Postgraduate Medicine. [DOI: 10.1080/00325481.2022.2069582] [Reference Citation Analysis]
6 Brent MB, Brüel A, Thomsen JS. Anti-sclerostin antibodies and abaloparatide have additive effects when used as a countermeasure against disuse osteopenia in female rats. Bone 2022. [DOI: 10.1016/j.bone.2022.116417] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Ullal J, Kutney K, Williams KM, Weber DR. Treatment of cystic fibrosis related bone disease. Journal of Clinical & Translational Endocrinology 2022;27:100291. [DOI: 10.1016/j.jcte.2021.100291] [Reference Citation Analysis]
8 Brent MB. A review of the skeletal effects of exposure to high altitude and potential mechanisms for hypobaric hypoxia-induced bone loss. Bone 2022;154:116258. [PMID: 34781048 DOI: 10.1016/j.bone.2021.116258] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]